APTN Stock — APTN

APTN (APTN)

Updated August 19, 2026.

APTN is a Stock. Total return is 12.0% over the past 0.3 years, 8.9 points ahead of SPY at 3.1%.

Adaptin Bio develops biotechnology products for cancer treatment using its BRiTE Platform technology, which employs fully human bispecific antibodies to redirect patients' T cells to recognize and destroy tumor cells. The company's pipeline includes APTN-101, a bispecific T cell engager in development for glioblastoma, breast cancer, and lung cancer, with a focus on enabling immunotherapeutic approaches that can cross the blood-brain barrier. As an early-stage biotech company, it does not currently distribute to shareholders.

APTN performance versus SPY

Price and return data through 2026-08-19.

Total return is 12.0% over the past 0.3 years, 8.9 points ahead of SPY at 3.1%.

APTN key facts

Asset type

Stock

Asset class

Equity

Inception date

05/14/2026

Distribution frequency

None

Last close

$6.27 (stale; as of 2026-08-19)

Average volume

200.0

Payout ratio

0.0%

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

Who may consider APTN — and who may not

It is a weaker fit for investors who need monthly cash flow (APTN does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on APTN

• All tickers starting with A

Frequently asked questions